Pfizer Inc. (PFE) Has Obtained Exclusive Commercialization Rights In Europe For CRESEMBA- OpGen, Inc. (OPGN)


Pfizer Inc. (NYSE:PFE) stock shows rises of 0.78% and traded at a price of $33.62 in preceding trading session. Pfizer Inc. (PFE) and BasileaPharmaceutica Ltd. (BSLN) reported that they have completed the licensing contract whereby Pfizer has obtained the exclusive commercialization rights in Europe to CRESEMBA (isavuconazole), a novel anti-fungal treatment for adult patients with diagnosed invasive aspergillosis and mucormycosis, two serious infections associated with high morbidity and mortality among immunocompromised patients.

Under the terms of the contract, Pfizer will have exclusive rights to distribute and commercialize CRESEMBA in Europe, including Austria, France, Germany, Italy, and the United Kingdom, where it is currently available . These rights do not extend to the Nordic countries (Denmark, Finland, Norway, Sweden, Iceland). Further, Pfizer will be responsible for additional CRESEMBA launches, predominantly in Europe, which are expected throughout 2017 and 2018. Basilea will remain the marketing approval holder for the European Union.

Its 52-week range quite noticeable, lower range was $12.71% and hit highest level of $-10.08%. The overall volume in the last trading session was 18.28 Million shares. The liquidity position of firm is on noticeable level, as its current ratio was calculated as 1.40 at the same time as its debt to equity ratio stands at 0.75.

Shares of OpGen, Inc. (NASDAQ:OPGN) at the time when day-trade ended the stock finally shows upbeat performance surged 5.96% to close at $0.32. OpGen, Inc. (OPGN) reported the closing of its previously reported public offering of 18,164,195 units at $0.40 per unit, and 6,835,805 pre-funded units at $0.39 per pre-funded unit, raising gross proceeds of around $10 million. The Company intends to use the net proceeds of this offering for general corporate purposes, including working capital and product development, particularly development of its rapid antibiotic resistance diagnostic product, and repayment of all outstanding bridge financing notes.

H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the offering. “We are pleased this public offering involving new and existing shareholders, as well as members of management, has been completed and look forward to advancing our business strategy,” said Evan Jones, chairman and chief executive officer of OpGen.

Each unit includes one share of common stock and one warrant to purchase one share of common stock at an exercise price of $0.425 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one warrant to purchase one share of common stock at an exercise price of $0.425 per share. The common warrants are exercisable immediately have a five-year term from the date of issuance.

The volatility tends to amount of risk or uncertainty about size of changes in a security’s value; a higher volatility denotes that a security’s value can potentially be spread out over a larger range of values. The price volatility of OPGN was 13.18% for a week and 14.25% for a month as well as price volatility’s Average True Range for 14 days was 0.07. Shares price isolated negatively from its 50 days moving average with -50.64% and remote negatively from 200 days moving average with -69.10%.


Please enter your comment!
Please enter your name here